Besufetamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the T-cell surface antigen CD3, with potential immunomodulatory and antineoplastic activities. Upon administration, besufetamig binds to both PD-1 expressed on activated T- and B-cells and certain malignant T-cells and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This may activate and redirect CTLs to PD-1-expressing cells, resulting in CTL-mediated killing of these cells. This may lead to anti-tumor activity in some T-cell lymphomas, and immunomodulatory activity in some autoimmune diseases.

**Synonyms:** - Anti-PD-1/Anti-CD3 Bispecific Antibody ONO-4685 - Anti-PD-1/CD3 Bispecific Antibody ONO-4685 - BESUFETAMIG - ONO 4685 - ONO-4685 - ONO4685 - PD-1 x CD3 Bispecific Antibody ONO-4685